Vivek Subbiah: “Pagers” are back in translational science
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X about a recent paper by Nicholas Kalogriopoulos et al. published in Nature:
“Wow! Published now in Nature.
If you thought ‘pagers’ in medicine were history – they are back in translational science!
- PAGERS are Programmable antigen-gated G-protein-coupled engineered receptors.
- PAGERs are responsive to more than a dozen biologically and therapeutically important soluble and cell-surface antigens and may have broad utility in discovery and translational science.
Congrats to the authors.”
“Synthetic GPCRs for programmable sensing and control of cell behaviour”
Authors: Nicholas Kalogriopoulos, Reika Tei, Yuqi Yan, Peter Klein, Matthew Ravalin, Bo Cai, Ivan Soltesz, Yulong Li and Alice Ting.
More posts featuring Vivek Subbiah.
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023